Important Protocol: Why Evenity Must Be Followed by an Antiresorptive Drug

Evenity (romosozumab) is a powerful osteoporosis treatment designed to build bone over a 12-month treatment course. However, its benefits can be quickly lost if therapy isn’t continued with an antiresorptive drug. Understanding why this transition is essential can help you protect your bone health and reduce fracture risk.

What Is Evenity (Romosozumab)?

Evenity is a monoclonal antibody that:

• Increases bone formation
• Decreases bone breakdown
• Is approved for postmenopausal women with high fracture risk

Key points:

• Dosage: 210 mg by subcutaneous injection once a month for 12 doses
• Mechanism: Blocks sclerostin, a protein that inhibits bone growth

FDA guidance and clinical studies show significant increases in bone mineral density (BMD) after 12 months of Evenity treatment.

Why the Transition Matters

The “Rebound” Effect

When Evenity is stopped without follow-up therapy:

• Bone turnover markers rise rapidly
• Bone density gains erode within months
• Fracture risk can return to—or even exceed—baseline

Studies indicate a substantial drop in hip and spine BMD over the year following Evenity discontinuation when no antiresorptive is started.

Maintaining Gains in Bone Density

Antiresorptive drugs (bisphosphonates or denosumab) work by:

• Slowing bone breakdown
• Preserving the new bone formed under Evenity
• Reducing long-term fracture risk

Without this “lock-in” effect, the benefits achieved during the 12-month Romosozumab course may be lost, undermining the initial treatment success.

Recommended Post-Evenity Antiresorptive Options

1. Oral Bisphosphonates
   • Alendronate (Fosamax®)
   • Risedronate (Actonel®)
     Advantages: Wide availability, low cost, long track record
2. Intravenous Bisphosphonates
   • Zoledronic acid (Reclast®) once yearly
     Advantages: Convenient annual dosing
3. Denosumab (Prolia®)
   • Subcutaneous injection every 6 months
     Advantages: Potent antiresorptive effect

Your doctor will personalize the choice based on:

• Kidney function
• Tolerance of oral medications
• Convenience and lifestyle
• Insurance coverage

Timing of the Transition

Best practices suggest:

• Start antiresorptive therapy within 4 to 6 weeks after the last Evenity injection
• Monitor bone turnover markers and BMD
• Reassess fracture risk annually

Delaying the switch increases the window for bone loss. Prompt initiation ensures continuous protection.

How to Talk to Your Doctor

Before making any changes:

• Share your full medical history (kidney health, dental health, other medications)
• Discuss any new symptoms (jaw pain, thigh pain)
• Ask about bone density testing schedules

You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to track any warning signs or side effects:
free, online symptom check, using the doctor approved Ubie Symptom Checker

Monitoring and Follow-Up

Even with proper transition:

• Schedule BMD scans every 1–2 years
• Check serum calcium and renal function as advised
• Report any new fractures or persistent pain immediately

Regular check-ins ensure the therapy remains safe and effective over time.

Practical Tips for Patients

• Keep a treatment calendar—mark Evenity and antiresorptive appointments
• Set reminders for blood tests and bone scans
• Stay active with weight-bearing exercises
• Ensure adequate calcium and vitamin D intake

These steps help reinforce the pharmacological benefits and support overall bone health.

Common Questions

Q: Can I take antiresorptive therapy before finishing all 12 months of Evenity?
A: Generally, no. Combining antiresorptives with Evenity may blunt its bone-building effect. Wait until the 12 doses are complete.

Q: What if I miss my antiresorptive dose?
A: Contact your healthcare provider promptly. Delays can permit bone loss.

Q: How long do I stay on antiresorptive therapy?
A: Many patients continue for several years. Your doctor will guide duration based on fracture risk and side effect profile.

Avoiding Common Missteps

• Don’t assume bone density gains are permanent without maintenance therapy.
• Never stop antiresorptive drugs abruptly—this can trigger rapid bone loss.
• Avoid unverified supplements or “natural” alternatives as substitutes for proven medicines.

Final Thoughts

Completing a Romosozumab 12 month treatment course is only half the battle. Following Evenity with a well-chosen antiresorptive drug is critical to:

• Preserve bone density gains
• Lower long-term fracture risk
• Maintain your quality of life

For tailored advice or if you experience worrisome symptoms, always speak to a doctor. Early intervention can prevent serious complications.

If you’re curious about any new symptoms, try a free, online symptom check, using the doctor approved Ubie Symptom Checker to get started. Then, schedule an appointment with your healthcare provider to discuss the safest path forward.